jc
jc

News Center

Check category
/
/
/
Zhang: Contribution to G20 National Science and Technology Exchange

Zhang: Contribution to G20 National Science and Technology Exchange

  • Categories:News Channel
  • Author:
  • Origin:
  • Time of issue:2017-02-03 14:56
  • Views:

(Summary description)

Zhang: Contribution to G20 National Science and Technology Exchange

(Summary description)

  • Categories:News Channel
  • Author:
  • Origin:
  • Time of issue:2017-02-03 14:56
  • Views:
Information

  "Financial Network" reporter Liu Xiang Li Hanwen reported in Suzhou


  In early September, the Group of Twenty (G20) leaders 11th summit held in Hangzhou, Zhejiang, G20 countries, technical cooperation and exchange between the international expectations of the meeting highlights. According to the People's Daily "Minsheng Weekly" reported that the medical field of J-Valve heart valve technology, is expected to become the Chinese science and technology sector on the G20 national technical exchange representative project.


  Zhang Ji, J-Valve technology inventor, Suzhou Jincheng Medical Technology Co., Ltd. founder, chairman, CEO. R & D innovation, healing, is his simple faith, "we can use our own research and development of medical technology to save people, to promote scientific and technological innovation with the scientific and technological reform, to 'China Heart' technology to the world, I think this is a very pleased "He said.


  G20 countries to contribute to technological exchanges
  Zhang was born in the doctor family, relatives are almost all doctors, wanted to become an engineer, but by the parents of life school doctor. Less than 28 years old on the operating table, and later go abroad for further study. In clinical practice, he always wanted to innovate. Before and after 2000, he found that the field of interventional valve is a medical and mechanical combination of the direction, then headlong into this area.


  At present, relying on his invention of the J-Valve valve replacement system, the treatment of aortic stenosis and valve insufficiency has achieved very good clinical results. And, surgery without thoracotomy for cardiopulmonary bypass, just open a hole in the intercostal through the catheter implantation of the valve.


  J-Valve technology has been initially in the field of valvular surgery in China to form a new treatment norms, according to clinical practice, the use of J-Valve technique for aortic valve replacement takes only 7 to 10 minutes. It is worth mentioning that clinical trials are high-risk elderly patients, the average age of 74 years of age, the highest age of 87 years of age. These elderly, critically ill patients, high success rate of surgery, postoperative recovery in good condition.


  Since the beginning of 2014, J-Valve valve replacement system has successively carried out clinical trials in three large well-known hospitals in China: West China Hospital of Sichuan University, Zhongshan Hospital of Fudan University in Shanghai and Fuwai Cardiovascular Hospital of Chinese Academy of Medical Sciences. Up to now has successfully completed more than 100 cases of clinical trials.


  The clinical case of the above-mentioned Chinese in the "American Journal of Cardiology" (JACC) published, the sensation of the global heart medical field. JACC is the world's leading journal of heart disease research, the world's only large, with significant clinical significance of the study can be published.


  This is also the Canadian "special grant" to carry out the first application from the Chinese medical products, an important reason for surgery.


  In February 2016, Canada's largest heart surgery center, Vancouver, St. Paul's Hospital, for a case of severe aortic insufficiency in patients with successful minimally invasive heart valve replacement. For his surgery is the Canadian health care workers, surgical use of medical equipment "special grant" from China - Zhang's entrepreneurial research and development team.


  In the past need a few hours or even ten hours of surgery, this time in the "minute" time to successfully end. The patient's surgery for 3 hours that is sitting to eat. Up to the current hospital follow-up shows that patients with good physical recovery.


  February 19, 1916, the success of the news came the first time, the Chinese Consul General in Vancouver Liu Fei met Zhang pole. Zhang Lei introduced the operation situation and J-Valve system characteristics, and stressed that this is all the independent intellectual property rights of China's innovative products, first applied to overseas patients and success for China's independent innovation of medical equipment to the international opened a new road.


  "This is the first time that China's independent intellectual property rights medical technology has entered the developed countries." Chinese Consul General Liu Fei in Vancouver said in an interview. Liu Fei expressed encouragement and support for promoting bilateral cooperation in science and technology.


  G20 summit will be held on the occasion, that J-Valve heart valve technology is expected to become G20 national technical exchange representative project, Zhang very calmly said: "as a young start-up enterprises, can gather in the giant medical field, J -Valve heart valve technology is expected to be presented as a representative project in front of the G20 countries, we are very pleased!


  "For J-Valve technology, has repeatedly appeared in the international arena, in the global field of cardiac care has aroused great concern. These are our encouragement, and our mission is to save lives, as soon as possible to save as much as possible Patient. "Zhang pole will always" cure "to worry about the heart.


  Spend less money to do big things, with science and technology to promote medical reform process


  "Financial Network": the current J-Valve technology research and development and promotion of how?


  Zhang pole: valve replacement technology in the sixties and seventies of last century has been more mature, but the replacement of artificial heart valve surgery is the biggest problem is that it needs to thoracotomy need extracorporeal circulation. Some patients who need to do this surgery are serious heart failure patients and elderly patients, most people can not afford to get this surgical approach.


  J-Valve minimally invasive valve replacement technology to make China's manufacturing and independent research and development capabilities to the world's top position, but also lead the Chinese medical equipment to the world's highest peak. It takes several hours for heart patients to have valve implantation in the past, and it takes only a few minutes to use J-Valve technology.


  J-Valve technology in the country has completed more than 100 cases of clinical trials. Four cases of surgery have been carried out in Canada, the patient recovery situation is very good, the Canadian government has gradually approved more patients using J-Valve minimally invasive valve. At the same time, Germany, Italy, Singapore and other developed countries, heart disease experts have also applied for the use of J-Valve minimally invasive valve, J-Valve technology is gradually to the global promotion.


  Why does J-Valve technology advance the health care system?


  Zhang: the world's health insurance budget is limited, the patient is often increasing. Heart failure is currently the world's first major cause of death, once the disease will consume a lot of medical resources. Traditional thoracic surgery risk, the effect is not ideal. However, if you do not do surgery, the patient also has a high annual cost to do conservative treatment, a few years down to spend a lot of money. Which is a considerable part of the cost is a financial burden. Now with more advanced technology, can reduce the burden on patients and the state.


  Medical field APPLE


  "Financial Network": You 25 years in Canada, has been fame, why now choose to return home business?


  Zhang: stay in Canada because there was able to learn more skills, to better play their own ability. Now return home business, I mainly think that this thing is beneficial to the patient. China now has a very good business environment and strong support of government departments at all levels, the Chinese patients will be more convenient to benefit, if the patients are benefiting, I think this is a very good thing.
  I personally feel that to cherish the lives of everyone, no matter who he is. From the doctor's point of view, if you invent a technology can cure people, the limitations of medical technology to narrow, you can save more people. In particular, for this valve disease, most of the critically ill patients do not bear thoracic surgery. J-Valve technology to solve this problem, then these patients will be able to live for many years.


  "Financial Network": science and technology innovation these years, have encountered any difficulties?


  Zhang: We are three people venture start, began to recruit only two technical staff and an administrative staff. At present, our team has developed to fifty or sixty people, able to complete the task on time and on budget.


  China's current innovative medical device company is not much, talent needs their own training. Our people in ordinary positions are progressing very fast, for example, they have not sewed the valve in the past, and now they have the technology, very stable, very good quality. Many people think that Apple's mobile phone quality is the best, I would like to put our involvement in the valve field into the medical field APPLE (apple).


  Our intervention in heart valve technology is now the sixth generation, but in fact the endless technology, we always feel that to continue to perfect, in every detail are thought to be further improved. Each link, every detail in accordance with standard specifications to do, strictly control the quality, the only way to maintain the clinical effect of stable and reliable.


  "Financial Network": the past few years has been concentrated in the stage of investment and development, the company has no income, right?


  Zhang: the company has nearly 7 years, has been a lot of money into research and development. Although the company has no income, but we have a very obvious progress for some time, which is the developer and investors are the biggest encouragement. For example, we in the animal experimental stage of the experimental results are very perfect, the clinical trial when the patient results in line with our expectations ... ... every link makes everyone confident.


  I believe that people have their own mission, perhaps my mission is to use my hands and brain for the treatment of human heart disease to provide a new method and means. Learn medicine for a lifetime, and then be able to invent a patient beneficial technology, it can completely change the treatment of a disease. I hope to be able to do this success, do the best.


  We are very grateful for the trust we have given to us. At the same time, we in the clinical trial of the patient's safety issues in the first place, from the technical point of view to fully consider the patient's safety and security.


  Bringing J-Valve technology to the world


  "Financial Network": the original is how to think of the invention of J-Valve?


  Zhang: I am the most headache and the most reluctant to say with the patient is a word, "we have no ability to treat your disease", in fact, this is a very big blow to the patient. In particular, many elderly people once had aortic valve disease and can not afford the cardiopulmonary bypass, can only go home before. This is my original invention J-Valve technology driving force.


  Before and after 1999, I still have part of the time to do clinical, when the intervention valve began to have the company in the study. I also participated in these studies very early, but I felt that the design was not reasonable. My initial idea is to make a system, so that the implant device automatically put the valve into the body, that is, automatic completion of the aortic valve replacement, do not need to rely on the doctor too much subjective experience. Some equipment depends on the doctor aimed, but the doctor tired or the image is not clear, it will cause a high rate of targeting error.


  I have been groping, experimenting, and making a prototype of the J-Valve valve. With the investment, further the development of this technology into the current J-Valve valve replacement system.


  What is the difference between J-Valve technology and other countries' existing technology?


  Zhang Jue: The main difference is that the design of J-Valve valve replacement system is more in line with the human anatomy, a good solution to the valve positioning and valve fixation and other key links, so that doctors operate more easily, the surgical process more secure and smooth Play a role in improving efficacy, reduce risk and reduce side effects. In addition, J-Valve system has a wider range of applications. J-Valve system can not only treat aortic valve stenosis, but also effective treatment of aortic valve insufficiency; and other interventional valves can only treat valvular stenosis, and can not be reliable and effective treatment of valve closure.

Contact us

这是描述信息

+86-512-63179788(WJ) | +86-512-63036288(SZ)

这是描述信息

Building4-1,Hi-Tech Park, Wujiang, Jiangsu Province, China

C21 Building, 218 Xinghu Street, Suzhou Industrial Park, China

这是描述信息

215200

FOLLOW US

这是描述信息

Mobile Website

这是描述信息

WeChat

Copyright ©  Suzhou Jiecheng Medical Technology Co., Ltd. 

这是描述信息